CA2478965A1 - Agents for corneal or intrastromal administration to treat or prevent disorders of the eye - Google Patents

Agents for corneal or intrastromal administration to treat or prevent disorders of the eye Download PDF

Info

Publication number
CA2478965A1
CA2478965A1 CA002478965A CA2478965A CA2478965A1 CA 2478965 A1 CA2478965 A1 CA 2478965A1 CA 002478965 A CA002478965 A CA 002478965A CA 2478965 A CA2478965 A CA 2478965A CA 2478965 A1 CA2478965 A1 CA 2478965A1
Authority
CA
Canada
Prior art keywords
urea
corneal
cornea
eye
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002478965A
Other languages
English (en)
French (fr)
Inventor
Vicken Karageozian
David Castillejos
John Park
Gabriel Arthuro Carpio Aragon
Jose Luis Gutierres Flores
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vitreo Retinal Technologies Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2478965A1 publication Critical patent/CA2478965A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA002478965A 2002-03-14 2003-03-14 Agents for corneal or intrastromal administration to treat or prevent disorders of the eye Abandoned CA2478965A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36397902P 2002-03-14 2002-03-14
US60/363,979 2002-03-14
PCT/US2003/007700 WO2003077898A1 (en) 2002-03-14 2003-03-14 Agents for corneal or intrastromal administration to treat or prevent disorders of the eye

Publications (1)

Publication Number Publication Date
CA2478965A1 true CA2478965A1 (en) 2003-09-25

Family

ID=28041849

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002478965A Abandoned CA2478965A1 (en) 2002-03-14 2003-03-14 Agents for corneal or intrastromal administration to treat or prevent disorders of the eye

Country Status (10)

Country Link
EP (1) EP1482922A4 (ru)
JP (1) JP2005522464A (ru)
KR (1) KR20040094793A (ru)
CN (1) CN1642536A (ru)
AU (2) AU2003213858A1 (ru)
BR (1) BR0308403A (ru)
CA (1) CA2478965A1 (ru)
MX (1) MXPA04008776A (ru)
RU (1) RU2363459C2 (ru)
WO (1) WO2003077898A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030199574A1 (en) 2000-03-02 2003-10-23 Vitreo-Retinal Technologies, Inc. Treatment of ophthalmic disorders using urea and urea derivatives
CN101231121B (zh) * 2007-01-24 2012-06-13 泰州乐金电子冷机有限公司 冰箱用托盘拉出装置
CN102859344A (zh) * 2010-03-12 2013-01-02 独立行政法人理化学研究所 用于生物材料的澄清试剂和其用途
US10444124B2 (en) 2011-05-20 2019-10-15 Riken Clarifying reagent for biological materials and use thereof
JP6433901B2 (ja) 2013-08-14 2018-12-05 国立研究開発法人理化学研究所 光透過性に優れた生物材料を調製するための組成物およびその利用
DE102013110608A1 (de) * 2013-09-26 2015-03-26 Florian Lang Substanz zur Hemmung von Gewebskalzifizierung, Gewebsfibrosierung und altersassoziierten Erkrankungen
CN110237238A (zh) * 2019-08-02 2019-09-17 山东省眼科研究所 Manf在促进角膜损伤修复中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470881A (en) * 1993-09-09 1995-11-28 West Virginia University Research Corporation Urea ophthalmic ointment and solution
IL145226A0 (en) * 1999-03-02 2002-06-30 Vitreo Retinal Technologies In Agents for intravitreal administration to treat or prevent disorders of the eye
ES2325360T3 (es) * 2002-02-13 2009-09-02 Vitreo-Retinal Technologies, Inc. Tratamiento de trastornos oftalmicos usando urea y derivados de urea.

Also Published As

Publication number Publication date
BR0308403A (pt) 2005-01-18
CN1642536A (zh) 2005-07-20
WO2003077898A1 (en) 2003-09-25
MXPA04008776A (es) 2005-04-19
RU2004129761A (ru) 2005-06-10
AU2003213858A1 (en) 2003-09-29
JP2005522464A (ja) 2005-07-28
KR20040094793A (ko) 2004-11-10
EP1482922A4 (en) 2005-06-08
RU2363459C2 (ru) 2009-08-10
EP1482922A1 (en) 2004-12-08
AU2009201897A1 (en) 2009-06-04
AU2009201897B2 (en) 2011-09-15

Similar Documents

Publication Publication Date Title
US7977385B2 (en) Agents for corneal or intrastromal administration to treat or prevent disorders of the eye
CHEN et al. Trabeculectomy with simultaneous topical application of mitomycin-C in refractory glaucoma
Taneri et al. Evolution, techniques, clinical outcomes, and pathophysiology of LASEK: review of the literature
US5627162A (en) Methods and means for control of proliferation of remnant cells following surgery
US5811446A (en) Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
AU2009201897B2 (en) Agents for corneal or intrastromal administration to treat or prevent disorders of the eye
Carones et al. Evaluation of photorefractive keratectomy retreatments after regressed myopic laser in situ keratomileusis
EP0809486B1 (en) Bio-erodible ophthalmic shield
Virasch et al. Reduced application time for prophylactic mitomycin C in photorefractive keratectomy
MXPA01011025A (es) Metodos bioquimicos que eliminan las cicatrices, opacificacion y la bruma de la cornea.
de Benito-Llopis et al. Comparison between LASEK with mitomycin C and LASIK for the correction of myopia of-7.00 to-13.75 D
US10016452B2 (en) Fibromodulin formulation for reducing corneal scarring
US20090099557A1 (en) Methods and compositions for optimizing the outcomes of refractive laser surgery of the cornea
Yee et al. Update on laser subepithelial keratectomy (LASEK)
Kymionis et al. Dry eye after photorefractive keratectomy with adjuvant mitomycin C
RU2485939C1 (ru) Офтальмологический препарат в виде глазных капель, содержащий дисульфирам и таурин
Mehlan et al. Safety and complications after three different surface ablation techniques with mitomycin C: a retrospective analysis of 2757 eyes
EP1173207B1 (en) Miotic agents and hypertonic agents containing ophthalmic compositions
KR100509421B1 (ko) 각막 상피하 혼탁 억제제
Chen et al. Evaluation of mitomycin C in reducing postoperative adhesions in strabismus surgery
AU2011254081A1 (en) Agents for corneal or inrastromal administration to treat or prevent disorders of the eye
IL163938A (en) Urea or urea derivatives for the treatment or prevention of eye diseases
Skuta Antifibrotic agents in glaucoma filtering surgery
CN102349901A (zh) 吡非尼酮在制备防治眼科手术后增殖性疾病的药物中的应用及其滴眼液
JP2018532753A (ja) 滅菌水性点眼液の治療的使用

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued